ARCH Venture Partners
Venture capitalChicago · Seed–Growth · 42 people tracked
Also known as Arch Asset Management Inc · ARCH Venture · ARCH VENTURE CORP · ARCH VENTURE MANAGEMENT LLC
Investment thesis
ARCH Venture Partners positions itself as a contrarian, bold investor that follows the science to found and build companies based on revolutionary technologies capable of improving lives. The firm emphasizes backing great science and partnering with strong founders to create disruptive companies. It takes a long-term view of company building and remains flexible in its approach, sizing investments in portfolio companies as needed. ARCH leverages an extended network of partners to help support companies from their early formation stages through to reaching their full growth potential.
Source: firm website, verified Aug 11, 2026.
Team · 42 people
from the firm's website & public directories
What they invest in
from 134 of 185 portfolio companiesBiotech ×113Medical Devices ×70Deep Tech ×44Healthtech ×40AI & Machine Learning ×33Digital Health ×20Enterprise Software ×5Hardware ×5
HQs:United States×101United Kingdom×2Switzerland×1China×1Germany×1Iceland×1
Investments · 185 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 72024 · 132023 · 42022 · 82021 · 112020 · 22019 · 12018 · 72017 · 52016 · 42015 · 1383 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)Mohammed Asmal(Chief Medical Officer)Ann Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)J. Michael Ramsey(Director)Christopher Brown(Executive Officer)Joseph Griffith IV(Executive Officer)Corey Steffek(Director)Kevin Knopp(Executive Officer, Director)
Board seatKeith CrandellKevin Hrusovsky· per SEC Form D
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)CAROLE HO(Director)John Evans(Executive Officer, Director)MARK FISHMAN(Director)
Board seatRobert NelsenKristina Burow· per SEC Form D
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Benjamin Cravatt, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)Carolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Zachary D. Hornby(Executive Officer, Director)Jonathan E. Lim, M.D.(Director)
Board seatKristina Burow· per SEC Form D
Boulder, US
Board seatRichard Heyman· per SEC Form D · $90M raise · filed Apr 2024
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Bryan Giraudo(Executive Officer)Faheem Hasnain(Executive Officer, Director)Russell Cox(Director)Renee Gala(Director)Laura Carter, Ph.D.(Executive Officer)Christian Waage(Executive Officer)
Board seatKristina BurowRobert Nelsen· per SEC Form D
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jose Baselga(Director)Kaye Foster-Cheek(Director)
Board seatRobert Nelsen· per SEC Form D
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Matthew Fust(Director)Kari Stefansson(Director)Joshua Pinto(Executive Officer)Maykin Ho(Director)Alaa Halawa(Director)Tamara Tompkins(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D
Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention.
BiotechDigital HealthHealthtechMedical DevicesLexington, US
John Connolly(Director)Douglas Cole(Director)David Walt(Director)Martin Madaus(Director)Dennis Sandstedt(Director)Ernest Orticerio(Executive Officer)
Board seatKeith Crandell· per SEC Form D
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Katrine Bosley(Director)Michael Gilman(Director)Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)
BoardAmir Nashat(Director)
Board seatKristina Burow· per SEC Form D
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Alan Buckler(Executive Officer)Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)David Hallal(Director)Michael Gilman(Director)Jeffrey Flier(Director)
Board seatKristina Burow· per SEC Form D · $47M raise · filed Jan 2018
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO and Board Member)Michael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)
BoardJames I. Healy(Director)
Board seatRobert Nelsen· per SEC Form D
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Rob Chess(Director)
BoardPaul Conley(Director)
Board seatKeith Crandell· per SEC Form D
San Francisco, US
Board seatRobert NelsenKristina BurowVicki Sato· per SEC Form D
BiotechLexington, US
Steven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)Jude Onyia(Director)Robert W. Hesslein(Executive Officer)Todd Carter(Executive Officer)
Board seatGeorge Scangos· per SEC Form D · $20M raise · filed Jan 2024
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Carole Ho(Executive Officer)Vicki L. Sato(Director)Nancy A. Thornberry(Director)Peter S. Klein(Director)Marc Tessier-Lavigne(Director)Jay T. Flatley(Director)
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)Jonathan E. Lim, M.D.(President and Executive Chairman)Gary Yeung, CFA(Chief Business Officer)Alexander W. Casdin(Director)James A. Bristol, Ph.D.(Director)
PartnerKristina Burow· quoted
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Co-Founder & Chief Technology Officer)
Scalable, high throughput DNA sequencing platforms.
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
HEIDI HENSON(Executive Officer)TROY WILSON(Executive Officer, Director)ANNETTE NORTH(Executive Officer)PINGDA REN(Executive Officer)YI LIU(Executive Officer)ANTONIO GUALBERTO(Executive Officer)
Maze Therapeutics develops precision medicines for kidney disease and other conditions with large unmet medical needs, using a genetic variant-based approach through its Compass platform.
BiotechMedical Devices
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.
BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US
Sylvie Gregoire(Director)Michel Vounatsos(Director)Samuel Chapin(Director)James M. Mock(Executive Officer)Andrew Okun(Executive Officer)Pascale Witz(Director)
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultDr. Sevigny
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)Ryan Helon(Director)Dan Myers(Director)Richard Shea(Executive Officer, Director, Promoter)
Board seatSteve Gillis· per SEC Form D
Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.
BiotechHealthtechMedical DevicesWoburn, US
Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)Denise Dajles, PhD(President & CEO)John McDonough(Executive Officer, Director)Keith Crandall(Director)
Board seatKeith Crandell· per SEC Form D
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)Jiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)Robert Carson(Executive Officer, Director)Terry Lo(Director)Seth Benson(Executive Officer)Simona Levi(Executive Officer)
Board seatKeith Crandell· per SEC Form D
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical Devices
Akin Akinc, Ph.D.(CEO)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Mark Murcko, Ph.D.(Director)Richard Young, Ph.D.(Director)Elisabeth Leiderman(Executive Officer)Ameet Nathwani, M.D.(Executive Officer, Director)Isaac Klein, M.D., Ph.D.(Executive Officer)Lori Escobedo(Executive Officer)
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical Devices
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)
Moleculent develops biological discovery and disease understanding tools for scientists.
AI & Machine LearningBiotechDeep Tech
Fredrik Roos(CTO & Co-founder)
Paradigm Health operates a platform that increases patient access to clinical trials through a provider-facing infrastructure combined with AI-powered research technology.
AI & Machine LearningHealthtechMedical DevicesSaaS
Kent Thoelke(Founder and CEO)Jonathan Hirsch(Chief Strategy and Growth Officer)
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)Gabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Jay Parrish(Chief Executive Officer & Chairman of the Board)
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer)
Sunnyvale, US
Narbeh Derhacobian(Executive Officer, Director)Barry Cox(Director)Matt Boyle(Director)Ron Shelton(Executive Officer)Alexei Andreev(Director)Nelson Chan(Director)
Board seatKeith Crandell· per SEC Form D · $12.5M raise · filed Sep 2015
AgTechResearch Triangle Park, US
Scott Uknes(Manager)Larry Robbins(Secretary)Thomas Dietz(Manager)John Ryals(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
Board seatKristina Burow· per SEC Form D · $34.5M raise · filed Aug 2015
Agrivida develops enzyme technology for animal feed and nutrition, improving efficiency in poultry, swine, and other livestock production.
AgTechBiotechFoodTechMassachusetts, US
Rob Johnson(Director)R. Michael Raab(Executive Officer)Daniel Meagher(Executive Officer, Director)Mark Austin(Director)Robert Bucklin(Director)Jeremy Schley Johnson(Executive Officer)
Board seatClinton Bybee· per SEC Form D
BiotechFramingham, US
Martin Tolar, M.D., Ph.D.(President and Chief Executive Officer)Glenn E. Pauly(Chief Commercial Officer)Susan Abushakra, M.D.(Chief Medical Officer)John Hey, Ph.D.(Chief Scientific Officer)Kenneth A. Mace(Treasurer and Chief Financial Officer)Adem Albayrak(Chief Data Officer)
Board seatScott Minick· per SEC Form D · filed Feb 2015
Brooklyn, US
Zen Chu(Director)Lis Rhodes(Executive Officer)Francois Kress(Executive Officer, Director)
BoardAdam D'Augelli(Director)
Board seatRobert Nelsen· per SEC Form D · $10M raise · filed Mar 2022
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)ANNIE HAZLEHURST(Director)FENG ZHANG(Director)
BoardDAVID R. WALT(Director)
Board seatKeith Crandell· per SEC Form D
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)Christopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)
BoardBenjamin Gomez(Director)Adam Koppel(Director)Michael E. Bozik(Director)
Board seatPaul Berns· per SEC Form D
HealthtechSeattle, US
Nathan Price(Director)Tim Kilgallon(Director)Clayton Lewis(Executive Officer, Director)
Board seatRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017
Autobahn develops medicines for central nervous system (CNS) disorders by leveraging regenerative mechanisms of the human body.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)
BoardThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Board seatKristina Burow· per SEC Form D
Research Triangle Park, US
Tracy Jackson(Executive Officer)John Dombrosky(Executive Officer)Joel Marcus(Director)Stephen Benkovic(Director)Paul Schimmel(Director)
Board seatKristina Burow· per SEC Form D · $10.5M raise · filed Mar 2017
Richmond
William Sims(Director)Kirk A. Washington(Director)Geoff Catherwood(Director)Thomas Bilbrough(Director)Calvin Wade Sheen(Executive Officer, Director)Jim Miller(Director)
Board seatClinton Bybee· per SEC Form D · $9.1M raise · filed Jan 2016
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Board seatSteven Gillis· per SEC Form D
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.
BiotechDigital HealthHealthtechMedical DevicesMadison, US
Michelle B. Arora(Director)Terrence P. Brady(Executive Officer)Jonathan Oliner(Executive Officer)Maneesh K. Arora(Executive Officer, Director, Promoter)
Board seatPaul Berns· per SEC Form D
BiotechSan Francisco, US
Thomas Hecht(Director)Sung Lee(Executive Officer, Director)Johanna Friedl-Naderer(Director)Natascha Schill(Executive Officer, Director)Vanina de Verneuil(Executive Officer)
Board seatGeorge Scangos· per SEC Form D · $400K raise · filed Apr 2023
BiotechSeattle, US
Thomas King(Director)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Steven Gillis(Executive Officer, Director, Promoter)Mark Roth(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer, Director)
Board seatSteven Gillis· per SEC Form D
AgTechVolga, US
Mark Hyde(Executive Officer)Gary Goplen(Director)Spencer Enninga(Director)Lewis Bainbridge(Director)Thomas J Kersting(Executive Officer)Mark Mickelson(Director)
Board seatRobert Nelsen· per SEC Form D · $230M raise · filed Oct 2022
IngredientWerks is a molecular farming company that engineers crops to produce animal-identical proteins as plant-based ingredients for the alternative protein food market.
AgTechBiotechFoodTechWoburn, US
Steve Snyder(Director)Clinton Bybee(Director)Ronald Warner Meeusen(Director)James Schultz(Director)Matthew Plavan(Executive Officer, Director)
Board seatClinton Bybee· per SEC Form D · $5M raise · filed Aug 2022
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(CEO & Founder)Duane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)
BoardVijay Pande(Director)
Board seatRobert Nelsen· per SEC Form D
BiotechSeattle, US
Howard Pien(Director)Hal Barron(Director)Hans Bishop(Executive Officer, Director, Promoter)Bernard J. Cassidy(Executive Officer)Rupert Vessey(Director)Robert Azelby(Executive Officer)
Board seatRobert Nelsen· per SEC Form D
BiotechAnn Arbor, US
Michael Hayden(Director)Michael Steinmetz(Director)Steven Gillis(Director)Paul Sekhri(Executive Officer)Timothy Mayleben(Director)
BoardRobert Kamen(Director)
Board seatKristina BurowSteven Gillis· per SEC Form D · filed Jun 2015
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 28
IPOs and acquisitions across the tracked portfolioPrime MedicineNASDAQ: PRME908 DevicesNASDAQ: MASSBeam TherapeuticsNASDAQ: BEAMBoundless BioNASDAQ: BOLDEnliven Therapeutics, Inc.NASDAQ: ELVNGossamer BioNASDAQ: GOSSGRAILNASDAQ: GRALNeumora TherapeuticsNASDAQ: NMRAQuanterixNASDAQ: QTRXScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeaport TherapeuticsNASDAQ: SPTXTwist BioscienceNASDAQ: TWSTVir BiotechnologyNASDAQ: VIRVoyager Therapeutics, Inc.NASDAQ: VYGRAgios PharmaceuticalsNASDAQ: AGIODenali TherapeuticsNASDAQ: DNLIErascaNASDAQ: ERASGenerate BiomedicinesNASDAQ: GENBIlluminaNASDAQ: ILMNKardiganNASDAQ: KARDKura OncologyNASDAQ: KURALyell ImmunopharmaNASDAQ: LYELMaze TherapeuticsNASDAQ: MAZEParabilis MedicinesNASDAQ: PBLSPerkinelmerNYSE: RVTYRapport TherapeuticsNASDAQ: RAPPVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companiesErasca · simplywall.st · Jul 19, 2026
Rapport Therapeutics · defenseworld.net · Jul 18, 2026
GRAIL · simplywall.st · Jul 17, 2026
Resilience · tectonicdefense.com · Jul 17, 2026
Homeward · fxstreet.com · Jul 17, 2026
Qubit · quantumzeitgeist.com · Jul 17, 2026
Maze Therapeutics · simplywall.st · Jul 17, 2026
Alnylam · investing.com · Jul 17, 2026
Fund performance · per public LP disclosures · 6
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| ARCH VENTURE FUND XIII LPLPs: Texas Municipal Retirement System, Carnegie Corporation of New York, University of Texas Investment Management Company | 2023 | — | 39.8% | 1.25x | 0.00x |
| Arch IX OverageLPs: North Carolina Retirement Systems | 2016 | — | 26.0% | 2.85x | 1.89x |
| ARCH VENTURE FUND VI LPLPs: California State Teachers' Retirement System, The Regents of the University of California, Ewing Marion Kauffman Foundation +1 more | 2003 | — | 2.4% | 1.24x | 1.24x |
| ARCH VENTURE FUND IX LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 24.2% | 2.58x | 1.53x |
| ARCH VENTURE FUND VII LPLPs: North Carolina Retirement Systems, The Regents of the University of California, University of Texas Investment Management Company | — | — | 37.8% | 4.83x | 4.60x |
| ARCH VENTURE FUND VIII LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 21.6% | 3.19x | 2.44x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ10 insider ownership filings (Forms 3/4/5)
at Kardigan, Inc. (KARD), Lyell Immunopharma, Inc. (LYEL), Metsera, Inc. (MTSR)
Files 13F institutional holdings reports · latest May 2026
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does ARCH Venture Partners invest at?
- ARCH Venture Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is ARCH Venture Partners's typical check size?
- ARCH Venture Partners typically writes checks of $50K – $250M.
- What sectors does ARCH Venture Partners focus on?
- ARCH Venture Partners focuses on Biotech, Deep Tech, Healthtech.
- Where is ARCH Venture Partners located?
- ARCH Venture Partners is headquartered in Chicago, US.
- Does ARCH Venture Partners lead rounds?
- ARCH Venture Partners typically participates in rounds rather than leading them.
Media · Podcasts & interviews
featuring the teamSteven Gillis, PhD | Managing Director | ARCH Venture Partners
Life Science Washington · Steven Gillis
Images
Co-investors · 96
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
General Catalyst is a venture capital and investment firm that backs founders across industries, with a strong focus on AI-driven transformation, fintech, healthcare, and other sectors.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
▶84 more co-investors
Sofinnova VenturesSamsara BioCapitalCanaan PartnersLux CapitalFlagship Pioneering+ND CapitalMenlo VenturesVenrockNorthpond VenturesFoothill Ventures5AM VenturesDomain AssociatesIn-Q-TelMedical Excellence CapitalArtis VenturesVersant VenturesSR One Capital ManagementCambridge Innovation CapitalVida VenturesM VenturesLightspeed Venture PartnersInsight PartnersInnovation EndeavorsMadrona Venture GroupS32Paladin Capital GroupAmino CapitalSofinnova PartnersForbionThe Column Group6 Dimensions CapitalLeaps by BayerVertical Venture PartnersRazor's Edge VenturesBain Capital Life SciencesHealthCapCure VenturesCortado VenturesSequoia CapitalCraft VenturesNew Enterprise Associates (NEA)Alumni VenturesNotable CapitalUnknown VenturesCoatue ManagementAtomicoGreycroftSignalFireSoftBank Vision FundMaveronFoundryParadigmKortschak Investments L.P.Two Sigma VenturesEntrepreneur First23andMeLOI VentureBaruch Future VenturesFormation GroupIncisive VenturesStrawberry Creek VenturesEQT Life SciencesTA VenturesNeotribe VenturesIlluminate VenturesArriveJohnson & Johnson Innovation – JJDCDeerfield Management CompanyMPM BioImpactPitbull VenturesAbingworthAt One Ventures7wire VenturesFrazier Healthcare PartnersWave Digital AssetsWaverley CapitalAndera PartnersAdvent Life SciencesDFJCatalio Capital ManagementVertex Ventures HCMatrix Capital ManagementAltitude Ventures Management, LlcGENERAL INCEPTION
Firms observed investing alongside ARCH Venture Partners, from public investor directories. Shared companies are the overlap with ARCH Venture Partners's recorded portfolio.
Similar investors
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Bessemer Venture Partners is a venture capital firm that partners with entrepreneurs from early stages through every stage of growth, publishing investment roadmaps across multiple technology sectors.